Literature DB >> 12017370

In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.

S Nomura1, A Nagayama.   

Abstract

The antibacterial activity of S-4661, a new parenteral carbapenem antibiotic, was assessed against the major urological pathogens isolated from patients with complicated urinary tract infections. S-4661 was slightly less active than imipenem and panipenem, but more active than meropenem and ceftazidime against Gram-positive bacteria. Against Gram-negative bacteria, S-4661 was similar to meropenem, similar to or more effective than imipenem, and more active than panipenem and ceftazidime. Thus S-4661 possesses potent and well-balanced wide-spectrum antibacterial activity against various urological pathogens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12017370     DOI: 10.1179/joc.2002.14.2.155

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  8 in total

1.  In vitro antimicrobial activity of doripenem, a new carbapenem.

Authors:  Yigong Ge; Matthew A Wikler; Daniel F Sahm; Renée S Blosser-Middleton; James A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  Panipenem/betamipron.

Authors:  Karen L Goa; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.

Authors:  Hannah M Wexler; Adrian E Engel; Daniel Glass; Calida Li
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Comparison of in Vitro Activity of Doripenem versus Old Carbapenems against Pseudomonas Aeruginosa Clinical Isolates from both CF and Burn Patients.

Authors:  Zoya Hojabri; Mohammad Ahangarzadeh Rezaee; Mohammad Reza Nahaei; Mohammad Hossein Soroush; Morteza Ghojazadeh; Tahereh Pirzadeh; Mostafa Davodi; Mona Ghazi; Reza Bigverdi; Omid Pajand; Mohammad Aghazadeh
Journal:  Adv Pharm Bull       Date:  2013-02-07

Review 5.  In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.

Authors:  C Lascols; P Legrand; A Mérens; R Leclercq; L Armand-Lefevre; H B Drugeon; M D Kitzis; C Muller-Serieys; M E Reverdy; M Roussel-Delvallez; C Moubareck; A Lemire; A Miara; M Gjoklaj; C-J Soussy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-19       Impact factor: 3.267

6.  Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Authors:  Ronald N Jones; Holly K Huynh; Douglas J Biedenbach
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 7.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Doripenem: a review of its use in the treatment of bacterial infections.

Authors:  Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.